within Pharmacolibrary.Drugs.ATC.J;

model J01MA21
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.89,
    Cl             = 0.16 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 100 / 1000000,
    adminCount     = 1,
    Vd             = 0.00136,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0205,
    Tlag           = 13.8
  );

  annotation(Documentation(
    info ="<html><body><p>Sitafloxacin is a fluoroquinolone antibiotic developed for the treatment of various bacterial infections including respiratory tract infections, urinary tract infections, and others. It exhibits broad-spectrum antibacterial activity. Sitafloxacin is approved and primarily used in Japan and some Asian countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult Japanese volunteers after oral administration of sitafloxacin hydrate 100 mg tablet.</p><h4>References</h4><ol><li><p>Sadahira, T, et al., &amp; Nasu, Y (2017). Clinical pharmacokinetics of oral levofloxacin and sitafloxacin in epididymal tissue. <i>Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy</i> 23(4) 214–217. DOI:<a href=&quot;https://doi.org/10.1016/j.jiac.2016.12.010&quot;>10.1016/j.jiac.2016.12.010</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/28089362/&quot;>https://pubmed.ncbi.nlm.nih.gov/28089362</a></p></li><li><p>Wu, G, et al., &amp; Shentu, J (2014). Pharmacokinetics and safety of sitafloxacin after single oral doses in healthy volunteers. <i>International journal of clinical pharmacology and therapeutics</i> 52(12) 1037–1044. DOI:<a href=&quot;https://doi.org/10.5414/CP202147&quot;>10.5414/CP202147</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/25250613/&quot;>https://pubmed.ncbi.nlm.nih.gov/25250613</a></p></li><li><p>Tsuruoka, S, et al., &amp; Yamagata, K (2013). Dialyzability and pharmacokinetics of sitafloxacin following multiple oral dosing in infected hemodialysis patients. <i>Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy</i> 17(3) 319–324. DOI:<a href=&quot;https://doi.org/10.1111/j.1744-9987.2012.01150.x&quot;>10.1111/j.1744-9987.2012.01150.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/23735148/&quot;>https://pubmed.ncbi.nlm.nih.gov/23735148</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end J01MA21;
